Product Pipeline
Apnimed is exploring novel oral therapeutics targeting sleep-related breathing diseases.
Program
Preclinical
Preclinical
Phase 1
Ph 1
Phase 2
Ph 2
Phase 3
Ph 3
Pre-Commercial*
Pre-Commercial*
AD109
AD109 is an investigational oral therapy, a pill designed to target the underlying neuromuscular dysfunction in people living with mild, moderate, and severe obstructive sleep apnea (OSA). This novel treatment targets the hypoglossal motor nucleus (HMN) to increase signals in the upper airway dilator muscles during sleep to limit or prevent airway collapse.
AD109 was studied in the now-complete Phase 2b MARIPOSA trial and is currently being evaluated in two Phase 3 clinical trials, SynAIRgy and LunAIRo.
Close*NDA Package under construction. Has not been submitted for regulatory review.
Innovation in OSA: AD109
Discover our paradigm-shifting investigational drug in development for OSA.
Explore Apnimed Clinical Trials
Get information on current trials and see results for completed ones.